Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. (Q38129331)

29 August 2017

title

Biomarkers for pancreatic cancer: promising new markers and options beyond CA 19-9. (English)

1 reference

29 August 2017

0 references

1 reference

Umashankar K Ballehaninna

series ordinal

1 reference

29 August 2017

Ronald S Chamberlain

series ordinal

1 reference

29 August 2017

publication date

17 August 2013

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

1 reference

29 August 2017

page(s)

3279-3292

1 reference

The epidemiology of pancreatitis and pancreatic cancer

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Proteomic analysis of pancreatic juice for the identification of biomarkers of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Proteome-based biomarkers in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

A compendium of potential biomarkers of pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Genetic alterations of K-ras, p53, c-erbB-2, and DPC4 in pancreatic ductal adenocarcinoma and their correlation with patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serine protease inhibitor Kazal type 1 promotes proliferation of pancreatic cancer cells through the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

European experts consensus statement on cystic tumours of the pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Proteomic profiling of pancreatic cancer for biomarker discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Capillary electrophoresis mass spectrometry-based saliva metabolomics identified oral, breast and pancreatic cancer-specific profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Stool testing for the early detection of pancreatic cancer: rationale and current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Stool DNA testing for the detection of pancreatic cancer: assessment of methylation marker candidates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Osteopontin expression is associated with improved survival in patients with pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Progress on molecular markers of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Advances in biomarker research for pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum Biomarker Panels for the Detection of Pancreatic Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Novel tumor marker REG4 detected in serum of patients with resectable pancreatic cancer and feasibility for antibody therapy targeting REG4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum biomarkers for improved diagnostic of pancreatic cancer: a current overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Soluble iC3b as an early marker for pancreatic adenocarcinoma is superior to CA19.9 and radiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum REG4 level is a predictive biomarker for the response to preoperative chemoradiotherapy in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Site-specific activation of AKT protects cells from death induced by glucose deprivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Molecular markers of pancreatic cancer: development and clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Genetic and epigenetic alterations in pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Molecular pathogenesis of pancreatic cancer: advances and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Retracted: Activated K-ras and INK4a/Arf Deficiency Cooperate During the Development of Pancreatic Cancer by Activation of Notch and NF-κB Signaling Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Mouse models of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Exploiting inflammation for therapeutic gain in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Current concepts and novel targets in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

miRNA in clinical practice: pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Diagnostic value of microRNA for pancreatic cancer: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Circulating microRNAs: molecular microsensors in gastrointestinal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Molecular pathology and genetics of pancreatic endocrine tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

MicroRNA Expression Abnormalities in Pancreatic Endocrine and Acinar Tumors Are Associated With Distinctive Pathologic Features and Clinical Behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Targeting miR-21 for the therapy of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Discovery of diagnostic biomarkers for pancreatic cancer in immunodepleted serum by SELDI-TOF MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Mining the malignant ascites proteome for pancreatic cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Strategies for discovering novel pancreatic cancer biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Possible detection of pancreatic cancer by plasma protein profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Tissue proteomics in pancreatic cancer study: discovery, emerging technologies, and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Proteomics in pancreatic cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Comprehensive Proteomic Analysis of Human Pancreatic Juice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Serum tumor antigen REG4 as a diagnostic biomarker in pancreatic ductal adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

CA 19–9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Proteomics in pancreatic cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13277-013-1033-3

Advances in pancreatic cancer detection

21 January 2018

1 reference

12 December 2020

Comparative proteomic analysis of human pancreatic juice: methodological study

1 reference

12 December 2020

The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal

1 reference

12 December 2020

CEACAM1, a novel serum biomarker for pancreatic cancer

1 reference

12 December 2020

Carbohydrate markers of pancreatic cancer

1 reference

12 December 2020

Proteomic approaches for serum biomarker discovery in cancer

1 reference

12 December 2020

microRNA signature for human pancreatic cancer invasion and metastasis

1 reference

12 December 2020

TPS and CA 19-9 measurements in the follow-up of patients with pancreatic cancer and chronic pancreatitis

1 reference

12 December 2020

Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue.

1 reference

12 December 2020

Biomarker Discovery of Pancreatic and Gastrointestinal Cancer by 2DICAL: 2-Dimensional Image-Converted Analysis of Liquid Chromatography and Mass Spectrometry

1 reference

12 December 2020

Role of tumor markers and mutations in cells and pancreatic juice in the diagnosis of pancreatic cancer

1 reference

12 December 2020

Multivariate analysis of six serum tumor markers (CEA, CA 50, CA 242, TPA, TPS, TATI) and conventional laboratory tests in the diagnosis of hepatopancreatobiliary malignancy

1 reference

12 December 2020

A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer

1 reference

12 December 2020

Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9

1 reference

12 December 2020

Evolution and dynamics of pancreatic cancer progression

1 reference

12 December 2020

Diagnostic value of tissue polypeptide specific antigen in patients with pancreatic carcinoma

1 reference

12 December 2020

Evaluation of osteopontin as biomarker for pancreatic adenocarcinoma.

1 reference

12 December 2020

10.1007/S13277-013-1033-3

Identifiers

DOI

1 reference

Dimensions Publication ID

29 August 2017

1037641433

0 references

1 reference